Abstract
Kidney cancer currently affects approximately 270,000 people worldwide. The knowledge about the molecular biology of this tumor allowed the development of tyrosine kinase inhibitory agents. The treatment of metastatic tumors with these inhibitors increases the overall survival of kidney cancer patients. However, there are important therapy-related adverse effects that decrease the patient…